福安药业 reported revenue of ¥0.84B for the period ended 2026-06-30, -8.8% year on year. Net income was ¥0.10B, a 11.4% net margin on a 39.6% gross margin. The largest revenue line is 制剂 at 58% of the total. Free cash flow for the period was ¥0.09B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.84B | -8.8% |
| Gross profit | ¥0.33B | — |
| Operating income | ¥0.11B | — |
| Net income | ¥0.10B | -15.3% |
| Gross margin | 39.6% | Net margin 11.4% |
| Revenue Q/Q | +6.0% | — |
| Segment | Revenue | Share |
|---|---|---|
| 制剂 | ¥0.48B | 57.5% |
| 原料药及中间体 | ¥0.32B | 38.0% |
| 其他(补充) | ¥0.03B | 3.9% |
| 药品经销及其他 | ¥0.00B | 0.5% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.51B | 60.4% |
| R&D | ¥0.05B | 5.5% |
| SG&A | ¥0.19B | 22.2% |
| Tax & other | ¥0.01B | 1.4% |
| Item | Amount |
|---|---|
| Total assets | ¥5.62B |
| Total liabilities | ¥1.22B |
| Shareholders' equity | ¥4.40B |
| Equity / assets | 78.3% |
| Operating cash flow | ¥0.10B |
| Capital expenditure | ¥0.01B |
| Free cash flow | ¥0.09B |
| Cash conversion (OCF / net income) | 193% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
长荣股份 ・ 长海股份 ・ 节能铁汉 ・ *ST纳川 ・ 翰宇药业 ・ 高盟新材 ・ 海伦哲 ・ 聚光科技 ・ 舒泰神 ・ *ST天喻 ・ 理邦仪器 ・ 欣旺达
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies